Spots Global Cancer Trial Database for Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
Official Title: A Phase I Open-label, Multi-center Dose-escalation Study to Determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
Study ID: NCT00420485
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate the Maximum Tolerated Dose and dose limiting toxicity of gimatecan administered orally in patients with advanced solid tumors
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Vancouver, British Columbia, Canada
MD Anderson Cancer Center - Orlando, Toronto, Ontario, Canada
Novartis Investigative Site, Copenhagen, , Denmark
Novartis Investigative Site, Dijon Cedex, , France
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Saint-Herblain Cedex, , France
Novartis Investigative Site, Toulouse, , France
Novartis Investigative Site, Mainz, , Germany
Novartis Investigative Site, Tubingen, , Germany
Novartis Investigative Site, Enschede, , Netherlands
Novartis Investigative Site, Oslo, , Norway
Novartis Investigative Site, Madrid, , Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
